<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13(15)</volume><submitter>Montes-Cano MA</submitter><pubmed_abstract>&lt;h4>Aim&lt;/h4>To assess whether CCL2 or interactions between this chemokine and its receptor (CCR2) are associated with outcomes of chronic hepatitis C and with responses to antiviral therapy.&lt;h4>Methods&lt;/h4>Two hundred and eighty-four patients with chronic hepatitis C and 193 non-infected matched controls were included in this study. Patients were categorized according to their Scheuer score of hepatic fibrosis as F0-F2 (n = 202) or F3-F4 (n = 82) and according to their response to anti-Hepatitis C virus (HCV) therapy as sustained response (SR, n = 101) or non-sustained response (NSR, n = 98). Genotyping of the -2518 (A/G) CCL2 was performed using PCR-RFLP, genotyping of the 190 (A/G) CCR2 using a PCR-ARMS system, and genotyping of the rs3138042 (G/A) CCR2 using Taqman probes.&lt;h4>Results&lt;/h</pubmed_abstract><journal>World journal of gastroenterology</journal><pagination>2187-92</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4146842</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>CCL2-2518 A/G and CCR2 190 A/G do not influence the outcome of hepatitis C virus infection in the Spanish population.</pubmed_title><pmcid>PMC4146842</pmcid><pubmed_authors>Garcia-Lozano JR</pubmed_authors><pubmed_authors>Aguilar-Reina J</pubmed_authors><pubmed_authors>Romero-Gomez M</pubmed_authors><pubmed_authors>Barroso N</pubmed_authors><pubmed_authors>Montes-Cano MA</pubmed_authors><pubmed_authors>Nunez-Roldan A</pubmed_authors><pubmed_authors>Gonzalez-Escribano MF</pubmed_authors></additional><is_claimable>false</is_claimable><name>CCL2-2518 A/G and CCR2 190 A/G do not influence the outcome of hepatitis C virus infection in the Spanish population.</name><description>&lt;h4>Aim&lt;/h4>To assess whether CCL2 or interactions between this chemokine and its receptor (CCR2) are associated with outcomes of chronic hepatitis C and with responses to antiviral therapy.&lt;h4>Methods&lt;/h4>Two hundred and eighty-four patients with chronic hepatitis C and 193 non-infected matched controls were included in this study. Patients were categorized according to their Scheuer score of hepatic fibrosis as F0-F2 (n = 202) or F3-F4 (n = 82) and according to their response to anti-Hepatitis C virus (HCV) therapy as sustained response (SR, n = 101) or non-sustained response (NSR, n = 98). Genotyping of the -2518 (A/G) CCL2 was performed using PCR-RFLP, genotyping of the 190 (A/G) CCR2 using a PCR-ARMS system, and genotyping of the rs3138042 (G/A) CCR2 using Taqman probes.&lt;h4>Results&lt;/h</description><dates><release>2007-01-01T00:00:00Z</release><publication>2007 Apr</publication><modification>2025-04-25T19:32:09.01Z</modification><creation>2024-11-12T10:43:55.233Z</creation></dates><accession>S-EPMC4146842</accession><cross_references><pubmed>17465499</pubmed><doi>10.3748/wjg.v13.i15.2187</doi></cross_references></HashMap>